Dyne Therapeutics, Inc. - 10-Q Filing

Dyne Therapeutics reports Q3 financial results including research and development expenses and details regarding Hercules Loan Agreement tranches.

SEC EDGAR ·

Tickers: $DYN

Read the full article at SEC EDGAR

More Regulatory news